THTakeshi Horii

Takeshi Horii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takeshi Horii has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk of severe lower extremity arterial disease in elderly Japanese patients with type 2 diabetes: a propensity score-matched model analysis of sodium-glucose cotransporter 2 inhibitors versus metformin

    by Takeshi Horii, Marina Kawaguchi, Yuichi Ikegami, Yoichi Oikawa, Akira Shimada, Kiyosi Mihara

    Introduction: Lower extremity arterial disease (LEAD) represents a significant atherosclerotic complication in patients with type 2 diabetes (T2D). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and metformin are commonly prescribed glucose-lowering agents that have demonstrated potential benefits in attenuating atherosclerosis progression. This study examined the impact of SGLT2is and metformin on the risk of developing severe LEAD in elderly patients with T2D. Research design and methods: This retrospective cohort study analyzed insurance data for individuals aged 65 years and older with advanced-age health insurance coverage, using health insurance claims and self-reported health check-up data. The observation start date was the initial prescription date of SGLT2is or metformin. Severe LEAD was defined as cases requiring revascularization after a LEAD diagnosis. We conducted a 3-year analysis using propensity score matching to compare the distinct effects of each drug on LEAD risk using a claims database. Results: The final population comprised 31,732 new SGLT2i and metformin users, divided into two groups (n=15,866 patients each). LEAD incidence rates were 2.10 and 2.69 per 1,000 person-years for metformin and SGLT2is, respectively. Compared with metformin, SGLT2is showed a higher HR for severe LEAD, especially in patients with a diastolic blood pressure (dBP) below 80 mm Hg (HR: 2.11; 95% CI: 1.01 to 2.30) and an estimated glomerular filtration rate between 30 and 60 mL/min/1.73 m2 (HR: 2.32; 95% CI: 1.09 to 2.94). Conclusion: The endothelial benefits of metformin, achieved without affecting hemodynamics, may be particularly effective in elderly patients with T2D and low dBP or impaired renal function. However, the presence of cardiovascular disease may often lead to the selection of SGLT2is. Nevertheless, prioritizing the use of metformin may be prudent when considering LEAD status.


  • Open Access

    Factors associated with severe lower extremity artery disease in type 2 diabetes based on a large scale claims database in Japan

    by Takeshi Horii, Marina Kawaguchi, Yuichi Ikegami, Yoichi Oikawa, Akira Shimada, Kiyoshi Mihara

    Diabetic foot lesions are becoming increasingly prevalent due to increases in type 2 diabetes (T2D), aging populations, and atherosclerotic diseases. Individuals with T2D with comorbid lower extremity artery disease (LEAD) are particularly susceptible. Although pharmacological therapies are often combined with risk management strategies, like exercise and smoking cessation, their roles in preventing LEAD progression are unclear. Herein, we investigated factors suppressing LEAD progression in T2D. Using data from the DeSC database, this retrospective cross-sectional study defined severe LEAD as a diagnosis requiring revascularization (Revasc). Logistic regression analysis was used to calculate odds ratios (ORs) for associated factors. The analysis included 243,606 patients with T2D divided into two groups; those with (n = 890) and without (n = 242,716) Revasc. Subgroup analysis of patients with LEAD (n = 27,258) with (n = 890) and without (n = 26,368) Revasc was also conducted. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) (OR 0.50), metformin (OR 0.78), and fibrates (OR 0.75) were associated with a significant reduction in severe LEAD in the primary and subgroup analyses. In conclusion, the active use of SGLT2 inhibitors, metformin, and fibrates may help prevent LEAD progression. However, these medications are associated with adverse events, making it essential to manage patients individually to optimize benefits while minimizing risks.

  • Open Access

    Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data

    by Takeshi Horii, Chikako Masudo, Yui Takayanagi, Yoichi Oikawa, Akira Shimada, Kiyoshi Mihara

    Adherence and treatment continuation rates of the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) semaglutide for both oral (O‐SEMA) and subcutaneous injection (SEMA‐SC) remain unknown in real‐world clinical practice. This retrospective observational study compared the 12 month adherence and treatment discontinuation of O‐SEMA and once‐weekly SEMA‐SC in patients with type 2 diabetes using a real‐world claims database. SEMA‐SC initiators were 1:1 propensity score‐matched to O‐SEMA initiators. Non‐adherence was defined as <0.8 of the proportion of days covered. SEMA‐SC had a significantly higher odds ratio (OR) for non‐adherence than O‐SEMA (OR: 1.39). The hazard ratio for treatment discontinuation, using O‐SEMA as the reference, was 1.45 for SEMA‐SC, although the discontinuation rate of O‐SEMA was higher during the early stage. O‐SEMA initiators showed significantly higher adherence and greater persistence in therapy than SEMA‐SC initiators at 12 months, which could lead to earlier initiation of GLP‐1RA treatment.


  • Open Access

    Factor affecting severe atherothrombotic cerebral infarction in patients with type 2 diabetes mellitus: Large‐scale claim database analysis of Japan

    by Takeshi Horii, Yoichi Oikawa, Kasumi Kidowaki, Akira Shimada, Kiyoshi Mihara

    Aims: This study aimed to investigate the factors associated with the exacerbation of the severity of atherothrombotic brain infarction at discharge in patients with type 2 diabetes using a large‐scale claims database.Materials and Methods: This retrospective cross‐sectional study utilized the Medical Data Vision administrative claims database, a nationwide database in Japan using acute care hospital data, and the Diagnosis Procedure Combination system. Diagnosis Procedure Combination data collected between April 1, 2008, and December 31, 2022, were extracted. Patients with type 2 diabetes were included. Severe atherothrombotic brain infarction was defined as a modified Rankin scale score of ≥3.Results: Severe atherothrombotic brain infarction occurred in 43,916/99,864 (44.0%) patients with type 2 diabetes. The odds ratio for severe atherothrombotic brain infarction increased significantly per 10 year increments in age (odds ratio: 1.69, 95% confidence interval: 1.66–1.71). A body mass index of 2, with a body mass index of ≥25 kg/m2 as reference, also increased the risk for severe atherothrombotic brain infarction (odds ratio: 1.11, 95% confidence interval: 1.08–1.15). The odds ratios in insulin and dipeptidyl peptidase 4 inhibitor use were significantly higher than 1. In particular, statin use (odds ratio: 0.85, 95% confidence interval: 0.83–0.88), fibrate use (odds ratio: 0.68, 95% confidence interval: 0.59–0.78), aspirin use (odds ratio: 0.78, 95% confidence interval: 0.75–0.80), and P2Y12 inhibitor use (odds ratio: 0.88, 95% confidence interval: 0.85–0.91) were associated with a lower odds ratio for severe atherothrombotic brain infarction.Conclusions: The active management of lipid levels using statins and fibrates may be beneficial in preventing the exacerbation of atherothrombotic brain infarction in type 2 diabetes patients.

  • Open Access

    Real‐world risk of cardiovascular diseases in patients with type 2 diabetes associated with sodium–glucose cotransporter 2 inhibitors in comparison with metformin: A propensity score‐matched model analysis in Japan

    by Takeshi Horii, Yoichi Oikawa, Akira Shimada, Kiyoshi Mihara

    We aimed to compare the effects of cardiovascular disease risk in Japanese patients with type 2 diabetes on sodium–glucose cotransporter 2 inhibitors (SGLT2Is) or metformin. This retrospective, real‐world cohort study was carried out using a claims database and propensity score matching; 58,402 eligible patients (29,201 per group) were included. The outcomes included nonfatal myocardial infarction, angina pectoris, nonfatal stroke, hospitalization for heart failure and composite end‐points. The hazard ratio (HR) for the composite end‐point was 0.79, which was lower for SGLT2Is than for metformin. For male patients (HR 0.76), patients aged 2 (HR 0.76), the HRs for the composite end‐point were significantly lower in the SGLT2I group than in the metformin group. SGLT2Is might be superior to metformin in reducing the composite risk of cardiovascular disease in patients with type 2 diabetes.


  • Open Access

    Risk of non-hypoglycemic agents for hypoglycemia-related hospitalization in patients with type 2 diabetes: a large-scale medical receipt database analysis

    by Takeshi Horii, Mai Otsuka, Takeo Yasu

    Introduction Hypoglycemia is listed as an adverse effect in the package inserts of not only hypoglycemic agents but also many other drugs. We aimed to clarify real-world factors related to an increased risk of hypoglycemia-related hospitalization (HRH) in Japanese patients with type 2 diabetes (T2D) on non-hypoglycemic agents that have been associated with hypoglycemia. Research design and methods This cross-sectional study was performed using data from the Medical Data Vision administrative claims database. We identified patients with T2D who were enrolled in the database between April 2014 and October 2019. Logistic regression analyses were performed to identify clinical factors associated with HRH due to non-hypoglycemic agents. Results Among 703 745 patients with T2D, 10 376 patients (1.47%) experienced HRH. The use of 332 non-hypoglycemic agents was associated with hypoglycemia. Multivariate analysis was performed to calculate OR for HRH. Seventy-five drugs had an OR greater than 1, and the values were significant. The OR was the highest for diazoxide (OR 15.5, 95% CI 4.87 to 49.3). The OR was higher than 2.0 for methylphenidate (OR 5.15, 95% CI 1.53 to 17.3), disulfiram (OR 4.21, 95% CI 2.05 to 8.62) and hydrocortisone (OR 2.89, 95% CI 1.11 to 7.51). Conclusion This large retrospective analysis revealed that the risk of HRH from some non-hypoglycemic agents in patients with T2D may be increased. The results of this study are expected to support treatment planning by physicians and healthcare professionals involved in diabetes care.


  • Open Access

    Real‐world risk of lower‐limb amputation associated with sodium–glucose cotransporter 2 inhibitors versus metformin: A propensity score‐matched model analysis in Japan

    by Gen Mizutani, Takeshi Horii, Yoichi Oikawa, Koichiro Atsuda, Akira Shimada

    Aims/Introduction We aimed to clarify the real-world risk of lower-limb amputation and identify factors related to increased risk in Japanese patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors (SGLT2is). Materials and Methods We carried out a retrospective observational cohort study utilizing the Japanese Medical Data Vision, a diagnosis procedure combination database. We identified 107,296 patients with type 2 diabetes who were initiated on SGLT2is or metformin (control; n = 53,648 per group) using 1:1 propensity score matching from April 2014 to October 2019. The hazard ratio (HR) for the risk of lower-limb amputation was analyzed using a Cox proportional hazards model adjusted for patients' baseline characteristics and use of concomitant medical agents. Results Of the 107,296 patients, 66 (0.06%); that is, 41 (0.08%) in the SGLT2is group and 25 (0.05%) in the metformin group, underwent amputation, with no significant difference in the proportions between the groups. There was no significant difference in the risk of amputation between the SGLT2is and metformin groups (HR 1.34, 95% confidence interval [CI] 0.80-2.24). However, female sex (HR 2.78, 95% CI 1.12-6.94) and use of strong statins (HR 2.68; 95% CI 1.18-8.20) were significantly associated with a higher risk of amputation in the SGLT2is group than in the metformin group. Conclusions SGLT2is might not be related to an increased risk of lower-limb amputation in patients with type 2 diabetes in real-world clinical practice. The possible increased risk of SGLT2is-associated amputation in female patients with type 2 diabetes and patients with type 2 diabetes requiring strong statins is notable.


  • Open Access

    Impact of intervention for self-management and glycemic control of patients with type 2 diabetes in community pharmacy setting

    by Takeshi Horii, Saki Hirano, Gaku Inoue, Koichiro Atsuda

    This study aimed to examine the impact of the Japanese version of the PHOND study technique delivered across five communities by community pharmacists for type 2 diabetes patients who are offered general diabetes treatment. The primary endpoints were changes in diabetes-related laboratory parameters such as haemoglobin A1c (HbA1c) levels and rates of health activity achievement. Sixty-four patients with type 2 diabetes were followed up for six months. HbA1c levels were lower at follow-up than at baseline in the group with baseline HbA1c 7.0% ≤ (7.5%±0.5 vs. 7.3%±0.5). Healthy activity engagement rates were higher at follow-up than at baseline (63.8point ±29.1 vs. 78.3point ±15.9). The PHOND study technique, which involves a collaboration between pharmacists and registered dietitians, may help provide access to care and promote self-management among patients with type 2 diabetes.